Biosimilars | Emerging Biosimilars | Emerging Biosimilars Landscape

Publish date: June 2019

Login to access report

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 400 currently available and novel biosimilar products, detailing information about the region(s) and their clinical phase of development. Additionally, we provide estimates for biosimilar launches in the seven major markets (United States, EU5, and Japan), as well as aggregate statistics to help answer key competitive intelligence questions. The Emerging Biosimilars Landscape is updated quarterly.

Questions Answered in This Report:

  • How many biosimilar candidates are currently undergoing phase I or III clinical development in a particular region?
  • Which biologic classes and reference molecules are most frequently targeted by biosimilars developers?
  • Which are the top 10 biosimilars developers by number of clinical stage candidates?
  • When is the expected launch date for late stage pipeline candidates in the seven major markets?
  • What is the level of competition expected for a brand, globally and by region/country?

Scope:

  • Markets covered: Global
  • Secondary research: clinical trial registries, company pipelines, annual reports, news articles, company press releases and presentations.

Mentioned in This Report:

Key Companies Mentioned

  • Amgen
  • Biocad
  • Biocon
  • Celltrion
  • Daiichi Sankyo
  • Dr. Reddy's
  • Fresenius Kabi
  • Gedeon Richter
  • Intas
  • Merck & Co
  • Mylan
  • Pfizer
  • Samsung Bioepis
  • Sandoz
  • Stada

Key Drugs Mentioned

  • Aranesp
  • Avastin
  • Enbrel
  • Erbitux
  • Forteo
  • Herceptin
  • Humira
  • Lantus
  • Neulasta
  • Neupogen
  • Remicade
  • Rituxan / MabThera

Table of contents

  • Emerging Biosimilars Landscape
    • Biosimilars Pipeline Analysis
      • Biosimilars Development Pipeline by Phase of Development
      • Biosimilars Development Pipeline by Class
      • Biosimilar Development Projects by Reference Molecule
      • Leading Biosimilars Developers
      • Biosimilar Launch Dates
    • Appendix
      • Methodology

Author(s): Jimmy Jacob

Jimmy Jacob, is a Business Insights Analyst in the Biosimilars team. Prior to joining DRG, Jimmy worked as a Scientist in Medimmune and Horizon Discovery mostly involving CRIPSR/Cas9 therapeutics. He received his master’s degree in Biotechnology from University of Dundee and his from Imperial College London. His work involved identifying novel molecules that regulated oestrogen receptor-alpha in breast cancer.